Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026

Eli Lilly flags counterfeit Mounjaro seizure in Gurugram

The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.

Pharma firms accelerate regional GLP-1 capacity to de-risk supply chains amid geopolitical tensions: GlobalData

At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen

GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access

FDA okays Eli Lilly’s new weight-loss pill, expanding options for millions

The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions

Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes

The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial